Sugar cubes & pills to prevent type 2.jpg

FOCUSED ON PEOPLE & THERAPIES

Thank you to all the investors!

which participated in our campaign on the Pipelbiz crowdfunding site (ended 24/09/2020).

We reached our goal of raising 4M NIS.

Developing Novel, First in Class Drugs, Treating and Preventing 

Type 2 Diabetes, Based on a Core-Technology-Platform.

Short Summary

Pipeline IND in process 

Type 2 Diabetes Drug

Professor Chevion and co-inventors developed a family of non-steroidal chemical complexes, made of components approved for clinical use.

 

These New Chemical Entities constitute a protected PLATFORM of DRUGS, with proven efficacy and complete safety, for treatments of multiple indications. Concenter BioPharma is developing and commercializing the drug which treats and prevents Type 2 Diabetes.

 

The drug has 3 synergistic Mechanisms of Action, extensively tested in animal models of human diseases 

(and anecdotal human cases).

Prof. DeFronzo presentation audio at the 17th World Congress

on Insulin Resistance. Diabetes & Cardiovascular Disease [2019]

Insulin Resistance All You Wanted to KnowProf. DeFronzo
Insulin syringe.jpg
 
ABOUT US & VISION

VISION

Becoming a global specialty biopharmaceutical company by advancing a pipeline of products that demonstrate vast potential for treating TYPE 2 DIABETES.

ABOUT

Concenter BioPharma is a subsidiary of Silkim Pharma Ltd., which developed a novel, protected PLATFORM of drugs for proven treatments of multiple indications. 

 Our PLATFORM is the result of extensive investigation of animal models of human diseases.

MEMBERS OF OUR PLATFORM ACT AS: 

Potent anti-inflammatory agents, Strong iron-chelating agents, and Anti-biotic agents. 

MORE ABOUT US
 
STRATEGY OVERVIEW

To rapidly advance from laboratory experiments to clinical trials in Type 2 Diabetes based on "shortcut"

regulatory routes, that enable a shorter time from the lab to treating patients.

 Our initial focus is on a leveraging FDA 505(b)(2) designations and Expedited Pathway programs.

​

Our focus leverages the global demand-creating patient population of about 450 million people with Diabetes.

 Our drug for treating Type 2 Diabetes (Pill) – extensively demonstrated as effective in both prevention and treatment of T2 Diabetes – by Restoring Insulin Resistance to Normal Levels!

Markedly inhibiting the appearance and the degree of hyperglycemia; lowering LDL; lowering body weight; reduction of cataract formation and diabetes-induced retinopathy. 

​

Errow icon.vestor art
All NEWS

SUBSCRIBE TO

Our Stay Tuned Emails...

​

Let The News
Come To You.

Thanks for submitting!

When you subscribe to our Stay Tuned emails,
the personal information you provide is used only to send the information you requested.
We will not share your personal data with any third party.